Search Results - Joo Y. Song

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial

    Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemo-immunotherapy on the SWOG S0016 trial by Alexey V. Danilov, Hongli Li, Mazyar Shadman, Lisa Rimsza, Ahmad Zebari, Sonali M. Smith, Michael LeBlanc, Jonathan W. Friedberg, Christopher Carlson, Joo Y. Song

    Published 2025-07-01

    Not available.

    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma

    Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma by Matthew Mei, Joycelynne Palmer, Hun Ju Lee, Iris Isufi, Robert Chen, Ni‐Chun Tsai, Saro Armenian, James Godfrey, Joo Y. Song, John H. Baird, Swetha Thiruvengadam, Yazeed Samara, Jessica Flores, Lacolle Peters, Steven Rosen, Larry Kwak, Stephen J. Forman, Alex F. Herrera

    Published 2025-05-01

    Abstract Nivolumab is an anti‐PD‐1 antibody that is effective in patients with relapsed/refractory (RR) classic Hodgkin lymphoma (cHL). We previously showed PET‐adapted sequential nivolumab ± ifosfamide, carboplatin, and etoposide (ICE) chemotherapy as the first salvage in RR cHL was a safe and effe...

    Full description

    Get full text
    Article

    Save to List
    Saved in:

Search Tools: